Please describe your practice as a clinician, how many patients with   HDV Infection do you see on a yearly basis? Could you walk us through the standard of care, and take us through the most promising upcoming treatments, or interesting clinical trials in this space?

How much of an unmet need is there in HDV? What would you like to see in the upcoming Phase 3 data readouts, in order to be convinced of the drugs’ efficacy?

How much use do you see for Lambda or Ritonavir, going forward? How likely are you to prescribe it to your patients?

Could you please describe to us in detail the mechanism of action of farnesyl-transferase inhibitors, the importance of inhibiting prenylation step of HDV replication inside liver cells and blocking the virus life cycle at the stage of assembly?

What are your thoughts regarding the longest duration of dosing standing at more than 10 years, considering pegylated interferon alpha is effective in reducing the viral load, with benefit generally stopping if the drug is discontinued, and efficiency standing at ~20%, with late relapses after therapy being reported?

How do you feel about either oral lonafarnib/ritonavir and combination with peginterferon alfa, in terms of efficacy?

Where would you situate the potential of Lambda to be interferon of choice in HDV combination therapies?